Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
C Mircea S TesileanuMarc SansonWolfgang WickAlba A BrandesPaul M J ClementSara C ErridgeMichael A VogelbaumAnna K NowakJean-Francois BaurainWarren P MasonHelen WheelerOlivier Louis ChinotSanjeev GillMatthew GriffinLeland RogersWalter TaalRoberta RudàMichael WellerCatherine McBainMyra E van LindeKenneth D AldapeRobert B JenkinsJohan M KrosPieter WesselingAndreas von DeimlingYouri HoogstrateIris de HeerPeggy N AtmodimedjoHendrikus Jan DubbinkRutger W W BrouwerWilfred F J Van IJckenKin Jip CheungVassilis GolfinopoulosBrigitta G BaumertThierry GorliaPim J FrenchMartin J Van Den BentPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
In this cohort of patients with glioblastoma, IDH-wt temozolomide treatment did not add benefit beyond that observed from radiotherapy, regardless of MGMT promoter status. These findings require a new well-powered prospective clinical study to explore the efficacy of temozolomide treatment in this patient population.